0000000000246599

AUTHOR

Blanca Navarro

showing 12 related works from this author

Impact of Clinical Features, Cytogenetics, Genetic Mutations and Methylation of CDKN2B and DLC-1 Promoters on Treatment Response to Azacitidine

2019

Introduction : Azacitidine (AZA) is a DNA hypomethylating agent used in myeloid neoplasms, however approximately half of patients show treatment failure or relapse. Last years, several studies have showed that genetic mutations may influence on response and survival of the treated patients. Other biomarkers that have traditionally been associated with the response to AZA are the recovery of the platelet count and the presence of abnormalities in the chromosome 7. Finally, the methylation dynamics of genes promoters could be a useful tool to predict the clinical response. Aim: To assess the predictive value on response to AZA of clinical features, cytogenetics, genetic mutations and the meth…

Mutationmedicine.medical_specialtyImmunologyAzacitidineCytogeneticsPromoterCell BiologyHematologyMethylationBiologymedicine.diseasemedicine.disease_causeBiochemistrychemistry.chemical_compoundchemistryCDKN2BChromosome abnormalitymedicineCancer researchDNAmedicine.drugBlood
researchProduct

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essent…

2010

Standardized criteria of response to treatment and a unified definition of resistance/intolerance to hydroxycarbamide (HC) in essential thrombocythaemia (ET) have been proposed by the European LeukaemiaNet (ELN). We have retrospectively evaluated such criteria in 166 ET patients treated with HC for a median of 4·5 years. Overall, 134 patients achieved a complete clinicohaematological response (CR) and 25 a partial response. Thirty-three patients met at least one of the ELN criteria defining resistance (n = 15) or intolerance (n = 21) to HC. Fifteen cases developed anaemia with thrombocytosis, which was associated with a high incidence of myelofibrosis and death from any cause. Other definit…

medicine.medical_specialtyThrombocytosisEssential thrombocythemiabusiness.industryIncidence (epidemiology)HematologyDrug resistancemedicine.diseaseThrombosisSurgeryHydroxycarbamideInternal medicinemedicineYoung adultMyelofibrosisbusinessmedicine.drugBritish Journal of Haematology
researchProduct

Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples.

2019

Background/aim Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy. Materials and methods We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients. Results The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis c…

MaleCancer ResearchMyeloidCurcuminAzacitidineAntineoplastic AgentsApoptosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineHumansAgedAged 80 and overbusiness.industryCell CycleMyeloid leukemiaCell DifferentiationDrug SynergismGeneral MedicineCell cyclemedicine.anatomical_structureOncologychemistryHypomethylating agentApoptosisLeukemia Myeloid030220 oncology & carcinogenesisMyelodysplastic SyndromesCancer researchCurcuminAzacitidineFemaleBone marrowbusinessmedicine.drugAnticancer research
researchProduct

Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with sur…

2018

Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in bone marrow samples from 353 adult acute myeloid leukemia (AML) patients and its relationship with several clinical, cytogenetic, and molecular variables. We also studied the expression of 84 genes involved in VEGF signaling in 24 patients. We found that VEGFC expression was higher in AML patients with myelodysplasia-related changes (AML-MRC) than in patients with non-AML-MRC. We also found an association between VEGFC expression and the patient cytogenetic risk group, with those with a worse prognosis having higher VEGFC expression leve…

AdultMale0301 basic medicineCancer ResearchAdolescentAngiogenesisVascular Endothelial Growth Factor CKaplan-Meier EstimateVEGFC expressionYoung Adult03 medical and health sciences0302 clinical medicineKDRBone Marrowhemic and lymphatic diseasesNeuropilin 1Biomarkers TumormedicineNRP1HumansGeneFLT1AgedChromosome AberrationsAcute myeloid leukemiaVascular Endothelial Growth Factor Receptor-1Cell growthbusiness.industryAdult Acute Myeloid LeukemiaHematologyVEGF signalingMiddle AgedPrognosismedicine.diseaseVascular Endothelial Growth Factor Receptor-2Neuropilin-1Leukemia Myeloid AcuteLeukemia030104 developmental biologymedicine.anatomical_structureOncologyVascular endothelial growth factor CMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchFemaleBone marrowbusinessLeukemia & Lymphoma
researchProduct

Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain

2018

Aim: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice. Methods: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015. Results: A total of 230 patients (mean age 76.9 ± 9.9 years; CHA2DS2-VASc 4.3 ± 1.7; HAS-BLED 1.7 ± 0.9) were included. Rates of stroke, major bleeding and intracranial bleeding were 0.4, 1.9 and 0.5 events per 100 patient-years, respectively. Conclusion: In this cohort of AF patients anticoagulated with rivaroxa…

Malemedicine.medical_specialtyHemorrhage030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanRisk FactorsInternal medicineAtrial FibrillationmedicineHumansIn patient030212 general & internal medicinePractice Patterns Physicians'StrokeAgedRetrospective StudiesAged 80 and overRivaroxabanbusiness.industryRetrospective cohort studyMean ageAtrial fibrillationmedicine.diseaseStrokeSpainCohortMolecular MedicineFemaleCardiology and Cardiovascular MedicinebusinessMajor bleedingFactor Xa Inhibitorsmedicine.drugFuture Cardiology
researchProduct

Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?

2021

Sodium-glucose co-transporter 2 inhibitors (iSGLT2) have been linked to cardiovascular risk reduction in patients with type 2 diabetes (T2D). However, their underlying molecular mechanisms remain unclear. This study aimed to evaluate the effects of empagliflozin, a novel potent and selective iSGLT-2, on anthropometric and endocrine parameters, leukocyte–endothelium interactions, adhesion molecules, ROS production, and NFkB-p65 transcription factor expression. According to standard clinical protocols, sixteen T2D patients receiving 10 mg/day of empagliflozin were followed-up for 24 weeks. Anthropometric and analytical measurements were performed at baseline, 12 weeks, and 24 weeks. Interacti…

Mitochondrial ROScardiovascular riskGPX1medicine.medical_specialtyEndotheliumPhysiologyClinical Biochemistryempagliflozin030209 endocrinology & metabolismLeukocyte RollingInflammationRM1-950030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineEmpagliflozinmedicineoxidative stressMolecular Biologybusiness.industryCell adhesion moleculeCommunicationCell Biologymedicine.anatomical_structureEndocrinologyinflammationtype 2 diabetesTherapeutics. Pharmacologymedicine.symptombusinessOxidative stressAntioxidants
researchProduct

Ighv Mutational Status By Deep Next Generation Sequencing Refines Ighv Sanger Sequencing Classification in Patients with Chronic Lymphocytic Leukaemia

2019

Introduction: Determination of the mutational status of rearranged immunoglobulin heavy chain variable (IgHV) genes in patients with Chronic Lymphocytic Leukaemia (CLL), is considered one of the most important prognostic factors: patients with unmutated IgHV (UM; ≥98% of identity to the germline) genes have a more aggressive disease course and develop more frequently unfavourable genetic deletions or mutations than patients with mutated IgHV (M; ≤98%). Mutational status, is currently determined by Sanger sequencing (Sseq) that allows the analysis of the major clone, however, international guidelines recommend caution in assigning mutational status in cases with "Borderline" IgHV identity (9…

Sanger sequencingGeneticsclone (Java method)ImmunologyLocus (genetics)Cell BiologyHematologyBiologyBiochemistryDNA sequencinglaw.inventionsymbols.namesakelawsymbolsMutation testingMultiplexIGHV@Polymerase chain reactionBlood
researchProduct

Efecto del telmisartán en el estrés oxidativo y actividad antioxidante en leucocitos de sangre periférica de pacientes hipertensos

2011

Resumen Introduccion Se han determinado el estres oxidativo y la actividad enzimatica antioxidante en leucocitos de pacientes hipertensos inmediatamente antes de iniciar el tratamiento con 80 mg/dia de telmisartan y despues de 2 meses de instaurada la medicacion. Adicionalmente se ha valorado en paralelo un grupo control. Material y metodos Como marcador de estres oxidativo, se ha determinado el potencial de membrana mitocondrial (ψΔ) en leucocitos. La actividad antioxidante se ha determinado midiendo la actividad superoxido dismutasa y catalasa en lisados leucocitarios. Resultados Nuestros resultados muestran mayor estres oxidativo y mayor actividad antioxidante en los pacientes en situaci…

Internal MedicineCardiology and Cardiovascular MedicineHipertensión y Riesgo Vascular
researchProduct

Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection.

2019

Abstract Background The specific characteristics of copy number variations (CNVs) require specific methods of detection and characterization. We developed the Easy One-Step Amplification and Labeling procedure for CNV detection (EOSAL-CNV), a new method based on proportional amplification and labeling of amplicons in 1 PCR. Methods We used tailed primers for specific amplification and a pair of labeling probes (only 1 labeled) for amplification and labeling of all amplicons in just 1 reaction. Products were loaded directly onto a capillary DNA sequencer for fragment sizing and quantification. Data obtained could be analyzed by Microsoft Excel spreadsheet or EOSAL-CNV analysis software. We d…

0301 basic medicineDNA Copy Number VariationsClinical BiochemistryComputational biologyPolymerase Chain Reaction03 medical and health sciences0302 clinical medicineHumansMultiplexMultiplex ligation-dependent probe amplificationCopy-number variationIn Situ Hybridization FluorescenceFluorescent DyesChemistryBiochemistry (medical)Sequence Analysis DNAAmpliconChromosome 17 (human)MSH6DNA sequencer030104 developmental biologyReceptors LDLMSH2030220 oncology & carcinogenesisDNA ProbesMultiplex Polymerase Chain ReactionClinical chemistry
researchProduct

Detection of Immunoglobulin Heavy Chain Gene Clonality By High-Throughput Sequencing for Minimal Residual Disease Monitoring in Chronic Lymphocytic L…

2019

Introduction: The negative minimal residual disease (MRD) after treatment has been recently accepted as endpoint for Chronic Lymphocytic Leukaemia (CLL) clinical trials. Conventionally, MRD can be detected by using multi-color Flow Cytometry (FC) with high sensitivity. Determination of the clonal immunoglobulin gene rearrangement can be a useful monitoring marker in a broad range of B-cell lymphoproliferative neoplasms. Moreover, the mutational status of immunoglobulin heavy chain variable (IgHV) rearrangement is considered one of the most important prognostic factors in CLL. Therefore, the identification of the IgHV rearrangement can be a useful marker both at diagnostic and as monitoring …

clone (Java method)Chronic lymphocytic leukemiaImmunologyCell BiologyHematologyComputational biologyBiologymedicine.diseaseBiochemistryMinimal residual diseasegenomic DNAEuroFlowhemic and lymphatic diseasesAcute lymphocytic leukemiamedicineMultiplexIGHV@Blood
researchProduct

Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A …

2018

Abstract Background Therapy-related acute myeloid leukemia (t-AML) develops in patients with prior exposure to cytotoxic therapies. Selection of a pre-existing TP53 mutated clone prone to acquire additional mutational events has been suggested as the main pathogenic mechanism of t-AML. Here, we report a unique case of t-AML which developed from a pre-existing DNMT3A mutated clone that persisted in the patient for more than 10 years despite treatment with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). Case presentation A 42-year-old male was diagnosed with AML harboring a normal karyotype and mutations in the NPM1 (c.863_864ins, p.W288 fs*12), DNMT3…

AdultMaleOncologymedicine.medical_specialtyNPM1Allogeneic transplantationmedicine.medical_treatmentClinical BiochemistryMutation MissenseClone (cell biology)Therapy-Related Acute Myeloid LeukemiaHematopoietic stem cell transplantationDNA Methyltransferase 3APathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansTransplantation HomologousDNA (Cytosine-5-)-MethyltransferasesMolecular BiologyBone Marrow Transplantationbusiness.industryMyeloid leukemiaInduction chemotherapyTransplantationLeukemia Myeloid Acute030220 oncology & carcinogenesisbusinessNucleophosmin030215 immunologyExperimental and Molecular Pathology
researchProduct

Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy

2019

There is evidence suggesting that cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be associated with a lower relapse incidence in acu...

Cancer Researchbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)De novo acuteCongenital cytomegalovirus infectionvirus diseasesMyeloid leukemiaHematologyHematopoietic stem cell transplantationCytotoxic chemotherapymedicine.disease03 medical and health sciencessurgical procedures operative0302 clinical medicineOncology030220 oncology & carcinogenesisCancer researchMedicineIn patientbusiness030215 immunologyLeukemia & Lymphoma
researchProduct